Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline

Jia Huang,1 Yun Wang,1 Jun Chen,1 Yanlei Zhang,2 Zheng Yuan,2 Li Yue,2 Josep Maria Haro,3 Maria Victoria Moneta,3 Diego Novick,4 Yiru Fang1,5,6 1Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2Medical Department, Eli Lil...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Huang J, Wang Y, Chen J, Zhang Y, Yuan Z, Yue L, Haro JM, Moneta MV, Novick D, Fang YR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Treatment observational study health outcomes functioning. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/bb7b29fd6d9e4e7ba39a12595ce76382
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:bb7b29fd6d9e4e7ba39a12595ce76382
record_format	dspace
spelling	oai:doaj.org-article:bb7b29fd6d9e4e7ba39a12595ce763822021-12-02T05:45:24ZClinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline1178-2021https://doaj.org/article/bb7b29fd6d9e4e7ba39a12595ce763822018-09-01T00:00:00Zhttps://www.dovepress.com/clinical-outcomes-of-patients-with-major-depressive-disorder-treated-w-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Jia Huang,1 Yun Wang,1 Jun Chen,1 Yanlei Zhang,2 Zheng Yuan,2 Li Yue,2 Josep Maria Haro,3 Maria Victoria Moneta,3 Diego Novick,4 Yiru Fang1,5,6 1Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2Medical Department, Eli Lilly and Company, Shanghai, China; 3Research, Teaching and Innovation Unit, Parc Sanitari Sant Joan De Déu, CIBERSAM, Universitat de Barcelona, Sant Boi De Llobregat, Barcelona, Spain; 4Health Outcomes, Eli Lilly and Company, Windlesham, Surrey, UK; 5State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences, CAS, Shanghai, China; 6Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China Purpose: To compare treatment outcomes in patients with major depressive disorder treated with duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline for up to 6 months. Patients and methods: Data were taken from a 6-month prospective, observational study that included 1,549 major depressive disorder patients without sexual dysfunction in 12 countries. We report the overall results and those from Asian countries. Depression severity was measured using the Clinical Global Impression and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Clinical and functional remissions were defined as having a QIDS-SR16 <6, and as having a rating of <3 on all three Sheehan Disability Scale items and no reduced productivity, respectively. Mixed effects modeling with repeated measures analysis and generalized estimating equation models were used. Propensity scores were included in the models. Results: The mixed effects modeling with repeated measures regression models showed that the Clinical Global Impression rating during follow-up was significantly lower in those patients treated with duloxetine compared with escitalopram (0.40, 95% CI 0.25 to 0.56); fluoxetine (0.22, 95% CI 0.05 to 0.38); paroxetine (0.38, 95% CI 0.23 to 0.54); and sertraline (0.32, 95% CI 0.16 to 0.49). The QIDS-SR16 of duloxetine-treated patients was significantly lower than those treated with escitalopram (1.58, 95% CI 1.03 to 2.12); fluoxetine (1.48, 95% CI 0.90 to 2.06); paroxetine (1.53, 95% CI 1.00 to 2.07); and sertraline (1.19, 95% CI 0.61 to 1.78). The probability of clinical remission of the patients treated with escitalopram, fluoxetine, paroxetine, and sertraline was lower than those treated with duloxetine (OR 0.46, 95% CI 0.33 to 0.64; OR 0.42, 95% CI 0.29 to 0.61; OR 0.40, 95% CI 0.29 to 0.56; OR 0.50, 95% CI 0.35 to 0.71; respectively). The regression analysis of functional remission also showed more favorable results for duloxetine, with OR ranging from 0.43, 95% CI 0.31 to 0.60 for paroxetine to 0.49, 95% CI 0.35 to 0.70 for sertraline. The results for the Asian countries were generally consistent. Conclusion: Duloxetine-treated patients had better 6-month outcomes in terms of depression severity and clinical and functional remission, compared with selective serotonin reuptake inhibitor-treated patients. Keywords: treatment, observational study, health outcomes, functioningHuang JWang YChen JZhang YYuan ZYue LHaro JMMoneta MVNovick DFang YRDove Medical PressarticleTreatmentobservational studyhealth outcomesfunctioning.Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 2473-2484 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Treatment observational study health outcomes functioning. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Treatment observational study health outcomes functioning. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Huang J Wang Y Chen J Zhang Y Yuan Z Yue L Haro JM Moneta MV Novick D Fang YR Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
description	Jia Huang,1 Yun Wang,1 Jun Chen,1 Yanlei Zhang,2 Zheng Yuan,2 Li Yue,2 Josep Maria Haro,3 Maria Victoria Moneta,3 Diego Novick,4 Yiru Fang1,5,6 1Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 2Medical Department, Eli Lilly and Company, Shanghai, China; 3Research, Teaching and Innovation Unit, Parc Sanitari Sant Joan De Déu, CIBERSAM, Universitat de Barcelona, Sant Boi De Llobregat, Barcelona, Spain; 4Health Outcomes, Eli Lilly and Company, Windlesham, Surrey, UK; 5State Key Laboratory of Neuroscience, Shanghai Institutes for Biological Sciences, CAS, Shanghai, China; 6Shanghai Key Laboratory of Psychotic Disorders, Shanghai, China Purpose: To compare treatment outcomes in patients with major depressive disorder treated with duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline for up to 6 months. Patients and methods: Data were taken from a 6-month prospective, observational study that included 1,549 major depressive disorder patients without sexual dysfunction in 12 countries. We report the overall results and those from Asian countries. Depression severity was measured using the Clinical Global Impression and the 16-item Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Clinical and functional remissions were defined as having a QIDS-SR16 <6, and as having a rating of <3 on all three Sheehan Disability Scale items and no reduced productivity, respectively. Mixed effects modeling with repeated measures analysis and generalized estimating equation models were used. Propensity scores were included in the models. Results: The mixed effects modeling with repeated measures regression models showed that the Clinical Global Impression rating during follow-up was significantly lower in those patients treated with duloxetine compared with escitalopram (0.40, 95% CI 0.25 to 0.56); fluoxetine (0.22, 95% CI 0.05 to 0.38); paroxetine (0.38, 95% CI 0.23 to 0.54); and sertraline (0.32, 95% CI 0.16 to 0.49). The QIDS-SR16 of duloxetine-treated patients was significantly lower than those treated with escitalopram (1.58, 95% CI 1.03 to 2.12); fluoxetine (1.48, 95% CI 0.90 to 2.06); paroxetine (1.53, 95% CI 1.00 to 2.07); and sertraline (1.19, 95% CI 0.61 to 1.78). The probability of clinical remission of the patients treated with escitalopram, fluoxetine, paroxetine, and sertraline was lower than those treated with duloxetine (OR 0.46, 95% CI 0.33 to 0.64; OR 0.42, 95% CI 0.29 to 0.61; OR 0.40, 95% CI 0.29 to 0.56; OR 0.50, 95% CI 0.35 to 0.71; respectively). The regression analysis of functional remission also showed more favorable results for duloxetine, with OR ranging from 0.43, 95% CI 0.31 to 0.60 for paroxetine to 0.49, 95% CI 0.35 to 0.70 for sertraline. The results for the Asian countries were generally consistent. Conclusion: Duloxetine-treated patients had better 6-month outcomes in terms of depression severity and clinical and functional remission, compared with selective serotonin reuptake inhibitor-treated patients. Keywords: treatment, observational study, health outcomes, functioning
format	article
author	Huang J Wang Y Chen J Zhang Y Yuan Z Yue L Haro JM Moneta MV Novick D Fang YR
author_facet	Huang J Wang Y Chen J Zhang Y Yuan Z Yue L Haro JM Moneta MV Novick D Fang YR
author_sort	Huang J
title	Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
title_short	Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
title_full	Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
title_fullStr	Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
title_full_unstemmed	Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
title_sort	clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/bb7b29fd6d9e4e7ba39a12595ce76382
work_keys_str_mv	AT huangj clinicaloutcomesofpatientswithmajordepressivedisordertreatedwitheitherduloxetineescitalopramfluoxetineparoxetineorsertraline AT wangy clinicaloutcomesofpatientswithmajordepressivedisordertreatedwitheitherduloxetineescitalopramfluoxetineparoxetineorsertraline AT chenj clinicaloutcomesofpatientswithmajordepressivedisordertreatedwitheitherduloxetineescitalopramfluoxetineparoxetineorsertraline AT zhangy clinicaloutcomesofpatientswithmajordepressivedisordertreatedwitheitherduloxetineescitalopramfluoxetineparoxetineorsertraline AT yuanz clinicaloutcomesofpatientswithmajordepressivedisordertreatedwitheitherduloxetineescitalopramfluoxetineparoxetineorsertraline AT yuel clinicaloutcomesofpatientswithmajordepressivedisordertreatedwitheitherduloxetineescitalopramfluoxetineparoxetineorsertraline AT harojm clinicaloutcomesofpatientswithmajordepressivedisordertreatedwitheitherduloxetineescitalopramfluoxetineparoxetineorsertraline AT monetamv clinicaloutcomesofpatientswithmajordepressivedisordertreatedwitheitherduloxetineescitalopramfluoxetineparoxetineorsertraline AT novickd clinicaloutcomesofpatientswithmajordepressivedisordertreatedwitheitherduloxetineescitalopramfluoxetineparoxetineorsertraline AT fangyr clinicaloutcomesofpatientswithmajordepressivedisordertreatedwitheitherduloxetineescitalopramfluoxetineparoxetineorsertraline
_version_	1718400253773742080

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline

Ejemplares similares